Phase I Study of Lapatinib in Combination With Trastuzumab
Latest Information Update: 06 Sep 2023
Price :
$35 *
At a glance
- Drugs Lapatinib (Primary) ; Trastuzumab
- Indications Breast cancer
- Focus Adverse reactions; Biomarker; Therapeutic Use
- Sponsors GSK
- 20 May 2011 Actual end date changed from Nov 2008 to Dec 2007 as reported by ClinicalTrials.gov.
- 14 Oct 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 04 Apr 2008 Status changed from recruiting to in progress, according to ClinicalTrials.gov.